Gan&Lee Pharmaceuticals. (ASX: 603087) has announced that it has received a drug registration approval from the Honduran National Drug Administration for its insulin glargine injection (prefilled pen).
Insulin glargine is a long-acting basal insulin administered via a single daily subcutaneous injection, providing blood sugar-lowering effects that last for 24 hours. This product is noted for its prolonged duration of action, stable blood concentration without peaks, and effective glycemic control.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments